.jpeg)
Will the targeted drug sotoraxib (AMG510) be included in medical insurance?
Sotoracib (AMG510)The original drug has not yet been marketed in China, so it has not been included in the national medical insurance, so the cost cannot be reimbursed through medical insurance. Sotoracib is a new, first-of-its-kind small molecule KRAS inhibitor and a targeted drug that specifically targets the KRAS G12C mutation. It is the world's first approved anti-tumor drug targeting KRAS mutations developed by the American company Amgen. Sotorasiib locks the KRAS G12C mutant protein in an inactive GDP-bound state, specifically and irreversibly inhibiting its pro-proliferative activity, thereby blocking the signaling pathways for tumor cell growth and spread.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
